0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Neurology |

This Month in Archives of Neurology FREE

Arch Neurol. 2011;68(12):1504-1505. doi:10.1001/archneurol.2011.1504.
Text Size: A A A
Published online

MAGNETIC RESONANCE TECHNIQUES IN MULTIPLE SCLEROSIS: THE PRESENT AND THE FUTURE

Filippi and colleaguesArticle discuss the application of new imaging modalities capable of measuring pathological processes related to the disease that have been neglected in the past (eg, iron deposition and perfusion abnormalities) and the advent of high- and ultrahigh-field magnets that have provided further insight into the pathobiological features of multiple sclerosis.

NO CEREBRAL OR CERVICAL VENOUS INSUFFICIENCY IN US VETERANS WITH MULTIPLE SCLEROSIS

Marder and colleaguesArticle report that their study does not support the theory that chronic cerebral venous insufficiency exists in multiple sclerosis. Editorial perspective is provided by Michael A. Williams, MD, and Arun Venkatesan, MD, PhDArticle.

EVIDENCE FOR ORDERING OF ALZHEIMER DISEASE BIOMARKERS

Jack et alArticle indicate a reduction in the cerebrospinal fluid (CSF) Aβ42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes.

 Image not available.

Box plots and superimposed data points showing the distribution of Alzheimer disease (AD) biomarkers by baseline diagnosis and visit. The horizontal line in each box indicates the median, whereas the top and bottom borders of the box mark the 75th and 25th percentiles, respectively. The whiskers above and below the box mark the largest and smallest data point that is within 1.5 times the interquartile range of the top and bottom of the box. A, For participants with both baseline and 12-month data, the cerebrospinal fluid (CSF) Aβ42 level did not change from baseline to 12 months in the cognitively normal (CN) group (P = .52), the mild cognitive impairment (MCI) group (P = .13), or the AD group (P = .51). B, The CSF total tau level is shown on the log scale. It increased from baseline to 12 months in CN participants (P = .002) but not in participants with MCI (P = .12) or AD (P = .36). The dotted horizontal line extending across all box plots represents the cut point denoting normal vs abnormal for each biomarker.

THROMBOLYTIC TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE RELATED TO UNDERLYING ARTERIAL DISSECTION IN THE UNITED STATES

Qureshi and colleaguesArticle find that the adjusted rate of favorable outcomes is lower among patients with ischemic stroke with underlying arterial dissection following thrombolytic treatment compared with those without underlying dissections. However, the observed lower rates are not influenced by thrombolytic treatment.

NEUROLOGICAL INJURY IN ADULTS TREATED WITH EXTRACORPOREAL MEMBRANE OXYGENATION

Mateen et alArticle show that severe neurological sequelae occur frequently in adult extracorporeal membrane oxygenation (ECMO)–treated patients with otherwise reversible cardiopulmonary injury (conservative estimate, 50%) and include a range of potentially fatal neurological diagnoses that may be due to the precipitating event and/or ECMO treatment.

TEN-YEAR OUTCOME OF SUBTHALAMIC STIMULATION IN PARKINSON DISEASE: A BLINDED EVALUATION

Castrioto and colleaguesArticle indicate that this class III study provides evidence that stimulation-induced motor improvement was overall sustained at 10 years, although part of the initial benefit wore off mainly because of progressive loss of benefit on axial signs over time.

MYASTHENIA GRAVIS–ASSOCIATED NEUROMYELITIS OPTICA–LIKE DISEASE: AN IMMUNOLOGICAL LINK BETWEEN THE CENTRAL NERVOUS SYSTEM AND MUSCLE?

Vaknin-Dembinsky et alArticle report that the incidence of central nervous system involvement in myasthenia gravis is higher than previously reported and is expressed predominantly as a pyramidal syndrome accompanied by optical tract involvement (frequently subclinical). These features bear some resemblance to neuromyelitis optica spectrum disease, supported also by the presence of anti-AQP4 antibodies in 7 of the 14 patients tested.

NEURODEGENERATION ACROSS STAGES OF COGNITIVE DECLINE IN PARKINSON DISEASE

Weintraub and colleaguesArticle find that hippocampal atrophy is a biomarker of initial cognitive decline in Parkinson disease, including impaired memory encoding and storage, suggesting heterogeneity in the neural substrate of memory impairment.

A COMPREHENSIVE GENETIC ASSOCIATION STUDY OF ALZHEIMER DISEASE IN AFRICAN AMERICANS

Logue et alArticle suggest that some genes contribute to Alzheimer disease pathogenesis in both white and African American cohorts, although it is unclear whether the causal variants are the same. A larger African American sample will be needed to confirm novel gene associations, which may be population specific.

THE APOE Ε2 ALLELE INCREASES THE RISK OF EARLIER AGE AT ONSET IN MACHADO-JOSEPH DISEASE

Bettencourt and colleaguesArticle provide findings that indicate that the polymorphism at the APOE gene plays a role as a genetic modifier of Machado-Joseph disease phenotype.

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

348 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs